RCS - Aquis Exchange PLC - Aquis Exchange recommences trading in Swiss shares

Aquis ExchangeAnnouncement

04/02/2021 08:06

RNS Number : 9248N
  
Aquis Exchange PLC
  
04 February 2021
  
 

4 February 2021
Aquis Exchange PLC
("Aquis" or the "Company")
Aquis Exchange recommences trading in Swiss shares
Aquis Exchange PLC (AQX.L), the exchange services group, is pleased to announce the resumption of trading in Swiss shares on its pan-European exchange facility, Aquis Exchange.
Following the UK government's agreement on equivalence with Switzerland, UK-based exchanges now have the ability to offer trading in Swiss shares. This follows the ban on EU venues from offering trading in Swiss shares, implemented in July 2019 after the EU did not renew equivalence with Switzerland.
The shares will be traded on Aquis Exchange's London venue, and include over 125 key Swiss names including Novartis, Roche and Nestlé.  
Alasdair Haynes, CEO of Aquis Exchange, said:
"We're pleased to once again be able to offer the trading of Swiss shares to our clients.
Jointly through our London and Paris venues, Aquis Exchange now covers 15 markets, with our clients continuing to benefit from our unique subscription pricing model, fast technology and deep liquidity on the Exchange."
- Ends -
Enquiries:



Aquis Exchange PLC


Tel: +44 (0) 20 3597 6321




Alasdair Haynes, CEO








Jonathan Clelland, CFO and COO








Belinda Keheyan, Head of Marketing


+44 (0) 7768 078 110














Liberum Capital Limited (Nominated Adviser and Joint Broker)


Tel: +44 (0) 20 3100 2000




Clayton Bush








Chris Clarke








Edward Thomas








Kane Collings


















Canaccord Genuity Limited (Joint Broker)


Tel: +44 (0) 20 7523 8000




Emma Gabriel (Corporate Broking)
Jeremy Grime (Specialist Sales)


















Alma PR (Financial PR Adviser)


Tel: +44 (0)20 3405 0209




Susie Hudson
Rebecca Sanders-Hewett


aquis@almapr.co.uk




Kieran Breheny
Faye Calow







 
Notes to editors:
Aquis Exchange PLC is an exchange services group, which operates pan-European cash equities trading businesses (Aquis Exchange), growth and regulated primary markets (Aquis Stock Exchange/AQSE) and develops/licenses exchange software to third parties (Aquis Technologies).
Aquis Exchange is authorised and regulated by the UK Financial Conduct Authority and France's Autorité des Marchés Financiers to operate Multilateral Trading Facility businesses in the UK and in the EU27 respectively. Aquis operates a lit order book and does not allow aggressive non-client proprietary trading, which has resulted in lower market impact and signalling risk on Aquis than other trading venues in Europe. According to independent studies, trades on Aquis are less likely to lead to price movement than on other lit markets. Aquis uses a subscription pricing model which works by charging users according to the message traffic they generate, rather than a percentage of the value of each stock that they trade.
Aquis Stock Exchange (AQSE) is a stock market providing primary and secondary markets for equity and debt products. It is authorised as a Recognised Investment Exchange, which allows it to operate a regulated listings venue.
Aquis Technologies is the software and technology division of Aquis Exchange PLC. It creates and licenses cutting-edge, cost-effective matching engine and trade surveillance technology for banks, brokers, investment firms and exchanges.
Aquis Exchange PLC (AQX.L) is listed on the Alternative Investment Market of the LSE (AIM) market. For more information, please go to www.aquis.eu
                
 
 
 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
NRAUPUUUPUPGGMW